A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Discover how AI is ...

Among other major losers, NEXON is plummeting almost 14 percent and Sumitomo Metal Mining is sliding almost 8 percent, while Daiichi Sankyo and JGC Holdings are ... Elsewhere in Asia, South Korea is ...

During the 31st APEC Economic Leaders' Meeting in Lima, Peru, this week, a milestone will be reached - the Chancay Port, controlled and invested by Chinese enterprises, is set to hold its operation ...

Earlier, o9 opened a new office in Shanghai, adding to its locations in Australia, India, Japan, Korea, and Singapore to better serve ... imaging and neuroscience with the... at 08:05 Daiichi Sankyo ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

The global vitamin and mineral market is estimated to be valued at USD 24.5 billion. Global sales of vitamins and minerals ...